• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

UCLA raises $611 million in 2020 –21, supporting students and advancing critical research
UCLA raised more than $611 million in gifts and pledges in the fiscal year ending June 30, exceeding its annual goal and drawing donors from all 50 states and 72 countries.“Generous donors at all levels have continued to partner with UCLA to effect meaningful change on campus, in the community and around the world,” said Chancellor Gene Block. “Despite a challenging year, our friends have once again demonstrated their extraordinary commitment to UCLA’s mission of education, research and service.”In response to conditions created by the COVID-19 pandemic, many donors focused on students ’ need to adapt to distan...
Source: UCLA Newsroom: Health Sciences - October 4, 2021 Category: Universities & Medical Training Source Type: news